今年三月CFO对cPass 的指引。We also launched cPass neutralizing antibody test kit.The product revenue reached $3.8
m in 2020. As cPass kit becomes available in more countries, the management team are
optimistic about the cPass kit's commercial potential. We expect the product to generate
considerable revenue for 2021 by expanding its presence and obtaining more approvals.$金斯瑞生物科技(01548)$